1. Scrip
  2. >>R&D

Takeda Highlights Value Of Late-Stage Pipeline

Peak Potential Of $10bn-20bn

 
• By Ian Haydock

Japanese major highlights at R&D Day key late-stage pipeline assets set to be filed for approval over the next few years, which it says have a combined peak sales potential of $10-20bn, and which could help it weather the expiry of current blockbuster Entyvio.

Takeda Tokyo HQ entrance
Takeda lays out prospects for late-stage pipeline • Source: Takeda

At a recent R&D Day, Takeda shone a spotlight on its late-stage pipeline, which in its view has a combined peak revenue potential of $10-20bn across six assets, within which Phase III readouts for three are expected next year.

Oveporexton (TAK-861), a first-in-class oral orexin receptor 2 agonist for narcolepsy Type 1, the TYK2 inhibitor zasocitinib (TAK-279) for psoriasis, and the injectable hepcidin mimetic rusfertide (TAK-121; partnered with Protagonist Therapeutics) in polycythemia vera will kick off what the major Japanese

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

More from Neurological